Official Title
Prognostic Value of Transcutaneous Partial Pressure of Oxygen in Patients With Novel Coronavirus Infection
Brief Summary

Five percent of patients with COVID-19 progressed to respiratory failure and required ICUadmission, such patients often have abnormal oxygen tolerance. However, there is still alack of clinical indicators to predict the prognosis and treatment responsiveness ofCOVID-19.

Detailed Description

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU
admission. Attention should be paid to patients over 65 years of age who have severe
underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular
diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not
completed the whole course of vaccine, and such patients often have abnormal oxygen
tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2)
can occur after daily activities. Basal SpO2 at admission is often associated with
prognosis, but it is difficult to differentiate prognosis from responsiveness to
treatment by changes in SpO2 after oxygen therapy is administered clinically. However,
there is still a lack of clinical indicators to predict the prognosis and treatment
responsiveness of COVID-19.

Recruiting
COVID-19 Acute Respiratory Distress Syndrome

Other: outcome

hospital survivors and nonsurvivors

Other: Subtype of COVID-19

Different subtype of COVID-19

Eligibility Criteria

Inclusion Criteria:

- Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging
features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial
partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest);

Exclusion Criteria:

- Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue
oxygen pressure monitoring; Clinicians believe that patients are not appropriate;
Patients undergoing ECMO.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 80 Years
Countries
China
Locations

Zhongda hospital
Nanjing, Jiangsu, China

Investigator: Jingyyuan Xu, MD
13851417209@163.com

Contacts

Jingyuan Xu, M.D.
008613851417209
13851417209@163.com

Jingyuan Xu, M.D., Principal Investigator
Southeast University

Southeast University, China
NCT Number
Keywords
ARDS
Respiratory failure
Covid-19
MeSH Terms
COVID-19
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury